Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Inhalation nebulizer

a nebulizer and inhalation technology, applied in the direction of medical atomisers, spraying apparatuses, liquid spraying apparatuses, etc., can solve the problem of enormous technical expenditure of automatic control of aerosol production

Inactive Publication Date: 2006-03-16
PARI PHARMA GMBH
View PDF22 Cites 68 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0009] The mixing chamber has an inhalation valve that allows ambient air to flow into the mixing chamber during an inhalation phase while preventing aerosol from escaping during an exhalation phase. The mixing chamber also has an exhalation valve that allows discharge of the patient's respiratory air during the exhalation phase while preventing an inflow of ambient air during the inhalation phase.

Problems solved by technology

Neither situation is flawless, as manual control of aerosol production is an additional strain for patients and often leads to insufficient results.
Automatic control of aerosol production represents an enormous technical expenditure which as a rule bears little relation to the obtained benefit.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inhalation nebulizer
  • Inhalation nebulizer
  • Inhalation nebulizer

Examples

Experimental program
Comparison scheme
Effect test

working example 1

[0083] The inhalation nebulizer described herein was used to test the atomization of two commercial products along with a novel submicron suspension. A salbutamol-sulfate solution available commercially as VENTOLIN™ (known generically as albuterol) was tested, as was a budesonide suspension sold under the name PULMICORT™. For comparison purposes, a novel submicron suspension of budesonide was also tested. Each solution or suspension was tested during continuous mode and during breath-triggered mode to evaluate the performance of the inhalation nebulizer.

[0084] Evaluation included looking at the percent of the test solution available for capture by an inhalation filter, as well as looking at product that remained in the mixing chamber, the fluid feed, or was otherwise lost or unrecoverable.

[0085] The results are depicted graphically in FIG. 4. The results indicate that deposition to an inhalation filter can be increased from about 50 percent to about 75 percent by operating in the ...

working example 2

[0086] The inhalation nebulizer described herein was tested against a commercially available product (the PARI LC STAR) using the three test components described in the previous Example. FIG. 5 provides results for the LC STAR and the results achieved by the inventive nebulizer (PEN). The results clearly indicate that the nebulizer in accordance with the invention provides for a higher proportion of drug available at smaller average particle sizes. Specifically, the MMAD is shifted from about 3.7 to 5.1 μm (for the PARI LC STAR) to about 2.2 to 3.9 μm for the inventive nebulizer.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

An inhalation nebulizer includes an aerosol generator that has a diaphragm vibrated by a vibration generator. The inhalation nebulizer includes a liquid storage container that is in fluid contact with the diaphragm. A liquid contained in the storage container is atomized into a mixing chamber through openings in the diaphragm and can subsequently be inhaled by a patient.

Description

TECHNICAL FIELD [0001] The invention relates generally to inhalation nebulizers and more specifically to inhalation nebulizers which form aerosols of liquid pharmaceuticals and liquids that contain pharmaceuticals. More specifically, the invention relates to inhalation nebulizers that form such aerosols medicaments while minimizing aerosol losses. BACKGROUND [0002] Inhalation nebulizers deliver therapeutically effective amounts of pharmaceuticals by forming an aerosol which includes particles of a size that can easily be inhaled. The aerosol can be used, for example, by a patient within the bounds of an inhalation therapy, whereby the therapeutically effective pharmaceutical or drug reaches the patient's respiratory tract upon inhalation. [0003] A variety of inhalation nebulizers are known. EP 0 170 715 A1 uses a compressed gas flow to form an aerosol. A nozzle is arranged as an aerosol generator in an atomizer chamber of the inhalation nebulizer and has two suction ducts arranged a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61M11/00B05B17/06A61M11/06A61M15/00
CPCA61M15/0085A61M15/0018A61M15/0015B05B17/0646
Inventor KNOCH, MARTINKELLER, MANFREDSTANGL, ROLANDGALLEM, THOMASLIENING-EWERT, RAINERURICH, MARKUS
Owner PARI PHARMA GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products